オプションチェーンは、Illuminaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Illuminaの市場センチメントを評価します。.

Illumina (NASDAQ:ILMN) 株価情報, オプションチェーン

ILLUMINA INC

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

News

Movers

COHR

COIN

CRWD

ESTC

GWRE

ILMN

NVDA

PLTR

RDDT

SAIA

大手株式のうち、先週利益が最も伸びた企業に投資していますか。以下は、先週における最大手株式の上位パフォーマンスについてのリストです。

アームとボーイング　大手株の中で大幅な上昇を記録

Illumina Inc

Illumina Inc COM-WHEN ISSUED

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) reported upbeat earnings for the first quarter, but lowered its FY25 guidance, <a href="https://www.benzinga.com/quote/ILMN/earnings">after the closing bell on Thursday.</a>
The company posted quarterly earnings of 97 cents per share which beat the analyst consensus estimate of 94 cents per share. The company reported quarterly sales of $1.04 billion which beat the analyst consensus estimate of $1.03 billion.
&#8220;I&#8217;m proud that the Illumina team delivered strong Q1 revenue and EPS, a good start to the year in an increasingly dynamic business environment,&#8221; said Jacob Thaysen, Chief Executive Officer. &#8220;Our outlook for the year has weakened due to shifting policy and geopolitical developments and we have taken swift incremental actions to protect our earnings. Our strategic focus remains on customer collaboration, driving differentiated innovations, and delivering on our long-term financial targets of growth and profitability.&#8221;
Illumina lowered its FY2025 adjusted EPS guidance from $4.50 to $4.20-$4.30 and sees core Illumina revenue to decline between (1%) and (3%) on a constant currency basis year over year.
Illumina shares gained 5.5% to trade at $79.92 on Monday.
These analysts made changes to their price targets on Illumina following earnings announcement.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst Kyle Mikson maintained Illumina with a Hold and lowered the price target from $92 to $87.</li>
<li>Morgan Stanley analyst Tejas Savant maintained the stock with an Equal-Weight rating and lowered the price target from $136 to $100.</li>
</ul>
Considering buying ILMN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12112455/image-128-1024x584.png" alt="" class="wp-image-912102" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12112455/image-128-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12112455/image-128-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12112455/image-128-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12112455/image-128.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45348276/marriott-international-to-rally-more-than-17-here-are-10-top-analyst-forecasts-for-monday">Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

Illumina Analysts Lower Their Forecasts After Q1 Results

Morgan Stanley analyst Tejas Savant maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Equal-Weight and lowers the price target from $136 to $100.

Morgan Stanley Maintains Equal-Weight on Illumina, Lowers Price Target to $100

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Hold and lowers the price target from $92 to $87.

Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $87

The Founder, CEO, and CIO of Ark Invest, Cathie Wood, has highlighted the rising applications of artificial intelligence and how it is poised to impact not only autonomous taxi networks and humanoid robots but also the health care space.
What Happened: According to ARK's proprietary Multiomics Flywheel, Wood highlighted in her recent X post that autonomous taxi networks and humanoid robots are likely to be the largest AI applications during the next five and ten years, respectively; however, &#8220;health care is likely to be the most profound.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While autonomous taxi networks and humanoid robots are likely to be the largest <a href="https://twitter.com/hashtag/AI?src=hash&amp;ref_src=twsrc%5Etfw">#AI</a> applications during the next five and ten years, respectively, health care is likely to be the most profound. Thank you <a href="https://twitter.com/NMDespotARK?ref_src=twsrc%5Etfw">@NMDespotARK</a> for thought leadership in the multiomics space! <a href="https://t.co/C33JfypivU">https://t.co/C33JfypivU</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1921291392271167893?ref_src=twsrc%5Etfw">May 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The post shared by Ark&#8217;s multiomics analyst, Nemo M Despot, underscored that &#8220;AI is powering a self-reinforcing loop that accelerates every aspect of multiomics—from generating biological data, to diagnosing diseases, to developing new drugs and cures.&#8221;
Multiomics is a biological analysis approach that integrates data from multiple &#8220;omic&#8221; fields, like genomics, transcriptomics, proteomics, and metabolomics, to gain an understanding of biological systems.
This integrated approach helps researchers uncover complex relationships, identify biomarkers, and ultimately understand the mechanisms behind disease and other biological processes.
He also highlights that companies like Twist Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 10X Genomics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), and Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) are developing increasingly powerful tools to sequence and analyze DNA faster and more cost-effectively.
Despot stated that AI-powered molecular diagnostics are transforming early disease detection and enabling precise stratification of individual patient biological profiles.
&#8220;AI leverages data from multiomic tools and diagnostics to design more effective drugs, delivering results with higher success rates more quickly and less expensively,&#8221; he said.
According to him, these next-generation therapies are:
<ul class="wp-block-list">
<li>Approximately 20 times more valuable than standard drugs.</li>
</ul>
<ul class="wp-block-list">
<li>Two to four times more effective than even today's best-in-class precision medicine.</li>
</ul>
<ul class="wp-block-list">
<li>The new cures can address even rare diseases economically.</li>
</ul>
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45340465/bill-ackman-slams-subsidies-for-contributing-to-37-trillion-national-debt-hails-trumps-drug-price-order">Bill Ackman Slams Subsidies For Contributing To $37 Trillion National Debt, Hails Trump&#8217;s Drug Price Order</a>
Why It Matters: Trump, in a Truth Social post, said that he will <a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran">sign an executive order</a> on Monday at 9:00 a.m. ET, which will lead the prescription drug and pharmaceutical prices to drop by 30% to 80%.
&#8220;They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA! I will be instituting a MOST FAVORED NATION'S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World,&#8221; he added.
Trump also believes that healthcare costs in the U.S. will be reduced after this move, and it would save &#8220;trillions of dollars.&#8221;
This action by Trump is anticipated to most significantly <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">affect Medicare Part B drugs</a>, primarily outpatient prescriptions and biological products, as their prices are directly controlled by the Centers for Medicare &amp; Medicaid Services (CMS).
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Drug Name</th>
<th>Manufacturer(s)</th>
<th>Total Spending</th>
<th>Primary Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keytruda</td>
<td>Merck &amp; Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) 
<path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path>
<div jsname="ntFePb" class="GRl5yb a8pxAe" style="max-height: 120px; visibility: inherit;"></div>
<div></div>
</td>
<td>$4.0B</td>
<td>Cancer (various types)</td>
</tr>
<tr>
<td>Eylea</td>
<td>Regeneron Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>$3.4B</td>
<td>Macular degeneration</td>
</tr>
<tr>
<td>Prolia/Xgeva</td>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>$2.1B</td>
<td>Osteoporosis, bone metastases</td>
</tr>
<tr>
<td>Opdivo</td>
<td>Bristol-Myers Squibb Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>$2.0B</td>
<td>Cancer (various types)</td>
</tr>
<tr>
<td>Darzalex</td>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>$1.9B</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Avastin</td>
<td>Roche Holdings AG&nbsp;(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTCQX">RHHBY</a>)</td>
<td>$1.8B</td>
<td>Cancer (various types)</td>
</tr>
</tbody>
</table>
</figure>
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Monday. The SPY was up 2.78% to $564.34, while the QQQ advanced 3.75% to $506.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Friday, the SPY was down 0.13% to $564.34, while the QQQ declined 0.066% to $487.97
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45341850/economists-warn-of-empty-shelves-if-goods-stop-coming-from-china-amid-falling-inventory-to-sales-ratio-and-potential-tariffs">Economists Warn Of &#8216;Empty Shelves&#8217; If Goods Stop Coming From China Amid Falling Inventory-To-Sales Ratio And Potential Tariffs </a></li>
</ul>
Photo Courtesy: PeopleImages- Yuri A On Shutterstock

Analyst Color

Equities

Government

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

ETFs

General

AMGN

REGN

RHHBY

TWST

Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$76.00</td>
<td>$46.3K</td>
<td>2.0K</td>
<td>4.3K</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$105.00</td>
<td>$32.6K</td>
<td>275</td>
<td>1.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$75.00</td>
<td>$45.3K</td>
<td>334</td>
<td>1.1K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$80.00</td>
<td>$32.1K</td>
<td>27</td>
<td>908</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$192.50</td>
<td>$25.0K</td>
<td>618</td>
<td>726</td>
</tr>
<tr>
<td>GH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$22.50</td>
<td>$46.7K</td>
<td>219</td>
<td>73</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/17/27</td>
<td>$500.00</td>
<td>$43.1K</td>
<td>494</td>
<td>41</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$790.00</td>
<td>$45.0K</td>
<td>160</td>
<td>12</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$490.00</td>
<td>$32.8K</td>
<td>21</td>
<td>8</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$280.00</td>
<td>$35.8K</td>
<td>1.7K</td>
<td>4</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option sweep that happens to be bullish, expiring in 7 day(s) on May 16, 2025. This event was a transfer of 315 contract(s) at a $76.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $46.3K, with a price of $147.0 per contract. There were 2065 open contracts at this strike prior to today, and today 4318 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with neutral sentiment. It expires in 133 day(s) on September 19, 2025. Parties traded 152 contract(s) at a $105.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $215.0 per contract. There were 275 open contracts at this strike prior to today, and today 1355 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 616 day(s) on January 15, 2027. Parties traded 27 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $45.3K, with a price of $1680.0 per contract. There were 334 open contracts at this strike prior to today, and today 1104 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a put option trade with bullish sentiment. It expires in 616 day(s) on January 15, 2027. Parties traded 6 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $32.1K, with a price of $5351.0 per contract. There were 27 open contracts at this strike prior to today, and today 908 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 7 day(s) on May 16, 2025. Parties traded 137 contract(s) at a $192.50 strike. This particular call needed to be split into 40 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $183.0 per contract. There were 618 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• For GH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), we notice a call option sweep that happens to be bullish, expiring in 224 day(s) on December 19, 2025. This event was a transfer of 22 contract(s) at a $22.50 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $46.7K, with a price of $2123.0 per contract. There were 219 open contracts at this strike prior to today, and today 73 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with neutral sentiment. It expires in 769 day(s) on June 17, 2027. Parties traded 10 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $43.1K, with a price of $4315.0 per contract. There were 494 open contracts at this strike prior to today, and today 41 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bullish sentiment. It expires in 98 day(s) on August 15, 2025. Parties traded 10 contract(s) at a $790.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $4500.0 per contract. There were 160 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be bearish, expiring in 161 day(s) on October 17, 2025. This event was a transfer of 5 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $32.8K, with a price of $6569.0 per contract. There were 21 open contracts at this strike prior to today, and today 8 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bullish, expiring in 616 day(s) on January 15, 2027. This event was a transfer of 4 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $35.8K, with a price of $8950.0 per contract. There were 1706 open contracts at this strike prior to today, and today 4 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

Hims & Hers Health, Inc. Class A Common Stock

HIMS

VKTX

VRTX

10 Health Care Stocks With Whale Alerts In Today's Session

Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Buy and lowers the price target from $122 to $114.

Guggenheim Maintains Buy on Illumina, Lowers Price Target to $114

WIIM

ILMN stock has given up its prior loss. Illumina shares were trading lower after the company reported Q1 financial results and cut its FY25 adjusted EPS guidance below estimates.

Illumina shares are trading lower after the company reported Q1 financial results and cut its FY25 adjusted EPS guidance below estimates.

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) lowers FY2025 Adj EPS guidance from $4.50 to $4.20-$4.30 vs $4.45 analyst estimate. Lowers FY2025 sales outlook from $4.28 billion-$4.40 billion to $4.20 billion-$4.29 billion vs $4.28 billion estimate.

Guidance

Illumina Lowers FY2025 Adj EPS Guidance from $4.50 to $4.20-$4.30 vs $4.45 Est; Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis YoY

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.94 by 3.19 percent. This is a 977.78 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $1.04 billion which beat the analyst consensus estimate of $1.03 billion by 0.99 percent. This is a 3.25 percent decrease over sales of $1.08 billion the same period last year.

Earnings Beats

Illumina Q1 Adj. EPS $0.97 Beats $0.94 Estimate, Sales $1.04B Beat $1.03B Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies
Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies
SAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), and Ovation.io, Inc.,&nbsp;an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. This collaboration is the latest in a series of efforts to partner across the ecosystem, and deploy multimodal data to advance a deeper understanding of biology.
One in eight adults in the United States have used a GLP-1 receptor agonist, according to a 2024 <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417889-1&amp;h=3609831402&amp;u=https%3A%2F%2Fwww.kff.org%2Fhealth-costs%2Fpoll-finding%2Fkff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs%2F&amp;a=health+tracking+poll">health tracking poll</a> conducted by the Kaiser Family Foundation. However, roughly 40% of users with Type 2 diabetes do not respond effectively to GLP-1 receptor agonists, according to a study <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417889-1&amp;h=668246930&amp;u=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fabs%2Fpii%2FS1871402124001474%3FviewFullText%3Dtrue&amp;a=published+in+Diabetes+%26+Metabolic+Syndrome">published in Diabetes &amp; Metabolic Syndrome</a> in 2024. The collaboration aims to accelerate GLP-1 therapy development, indication expansion research, and discovery of novel biomarkers and drug targets in nonresponsive populations.

Biotech

Illumina And Ovation.io Launching GLP-1 Dataset To Accelerate New Therapy Development

Across the recent three months, 16 analysts have shared their insights on Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Illumina, revealing an average target of $127.06, a high estimate of $247.00, and a low estimate of $77.00. This current average has decreased by 15.4% from the previous average price target of $150.19. 
<img src="https://www.benzinga.com/files/images/story/2025/1745935210_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Illumina. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $92.00&#x7C;$115.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $77.00&#x7C;$100.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $112.00&#x7C;$128.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $85.00&#x7C;$90.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $128.00&#x7C;$247.00 &#x7C; 
&#x7C;Mason Carrico &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $156.00&#x7C;$156.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $115.00&#x7C;$135.00 &#x7C; 
&#x7C;Catherine Ramsey &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$127.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$130.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $136.00&#x7C;$150.00 &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $190.00&#x7C;$185.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $100.00&#x7C;$130.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $247.00&#x7C;$250.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $135.00&#x7C;$145.00 &#x7C; 
&#x7C;Subbu Nambi &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$170.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $130.00&#x7C;$145.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Illumina. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Illumina's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Illumina's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Discovering Illumina: A Closer Look</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Understanding the Numbers: Illumina's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Illumina's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -1.6%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Illumina's net margin excels beyond industry benchmarks, reaching 16.94%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Illumina's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.31% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Illumina's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.04%, the company showcases efficient use of assets and strong financial health.
Debt Management: Illumina's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Illumina: Insights From 16 Financial Analysts

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Hold and lowers the price target from $115 to $92.

Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $92

April 18, 2025 records indicate that Representative Thomas Kean filed a purchase of Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), valued between $3,003 and $45,000. According to the April filing, the transaction occurred on April 18, 2025.
Currently, Illumina shares are trading down 0.23% at $71.03.
<h3>What Representative Has Been Trading Recently</h3>
In the last three years, Thomas Kean completed 79 stock transactions totaling more than $345 thousand. Aon and Johnson &amp; Johnson stocks were among the largest trades. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>): $15,001 - $50,000 Purchase</li>
<li>Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>): $1,001 - $15,000 Purchase</li>
<li>nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of Thomas Kean's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Illumina</td>
<td>ILMN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-04-01</td>
</tr>
<tr>
<td>nVent Electric</td>
<td>NVT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-04-01</td>
</tr>
<tr>
<td>nVent Electric</td>
<td>NVT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-07</td>
</tr>
<tr>
<td>Amazon.com</td>
<td>AMZN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-02-26</td>
</tr>
<tr>
<td>Stryker</td>
<td>SYK</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S (Partial)</td>
<td>2025-02-26</td>
</tr>
</tbody>
</table>
To keep an eye on Thomas Kean's trades and other government stock activity, check out our <a href="https://www.benzinga.com/gov-trades/members/thomas-kean">real-time tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Politics

Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease
SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ --&nbsp;Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) and Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.

Illumina And Tempus AI Collaborate To Accelerate Clinical Adoption Of Next-generation Sequencing Tests Through Novel Evidence Generation

Barclays analyst Luke Sergott maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Underweight and lowers the price target from $100 to $77.

Barclays Maintains Underweight on Illumina, Lowers Price Target to $77

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and lowers the price target from $128 to $112.

RBC Capital Maintains Outperform on Illumina, Lowers Price Target to $112

In the preceding three months, 14 analysts have released ratings for Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $135.86, along with a high estimate of $247.00 and a low estimate of $85.00. Experiencing a 14.17% decline, the current average is now lower than the previous average price target of $158.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744048815_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Illumina among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $85.00&#x7C;$90.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $128.00&#x7C;$247.00 &#x7C; 
&#x7C;Mason Carrico &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $156.00&#x7C;$156.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $115.00&#x7C;$135.00 &#x7C; 
&#x7C;Catherine Ramsey &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$127.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$130.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $136.00&#x7C;$150.00 &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $190.00&#x7C;$185.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $100.00&#x7C;$130.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $247.00&#x7C;$250.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $135.00&#x7C;$145.00 &#x7C; 
&#x7C;Subbu Nambi &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$170.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $130.00&#x7C;$145.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $150.00&#x7C;$156.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illumina. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Illumina's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Illumina's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Get to Know Illumina Better</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>A Deep Dive into Illumina's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Illumina's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -1.6% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Illumina's net margin is impressive, surpassing industry averages. With a net margin of 16.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Illumina's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.31%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Illumina's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.04% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Illumina's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Illumina Stock: Analyst Perspectives (14 Ratings)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup cut Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) price target from $90 to $85. Citigroup analyst Patrick Donnelly maintained a Neutral rating. Illumina shares closed at $74.16 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings">view this stock</a>.</li>
<li>Guggenheim slashed the price target for First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) from $304 to $253. Guggenheim analyst Joseph Osha maintained a Buy rating. First Solar shares closed at $128.69 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/FSLR/analyst-ratings">view this stock.</a></li>
<li>Barclays raised Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) price target from $27 to $29. Barclays analyst Andrew Lazar maintained an Overweight rating. Conagra shares closed at $26.68 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/CAG/analyst-ratings">view this stock</a>.</li>
<li>Susquehanna cut the price target for Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) from $34 to $25. Susquehanna analyst Christopher Stathoulopoulos maintained a Neutral rating. Southwest Airlines shares closed at $25.87 on Friday. <a href="https://www.benzinga.com/quote/LLUV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut the price target for Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from $325 to $250. Wedbush analyst Daniel Ives maintained an Outperform rating. Apple shares closed at $188.38 on Friday. See how other analysts view<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings"> this stock</a>.</li>
<li>Jefferies cut Sonos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONO#NASDAQ">SONO</a>) price target from $19 to $13. Jefferies analyst Brent Thill maintained a Buy rating. Sonos shares settled at $8.60 on Friday. <a href="https://www.benzinga.com/quote/SONO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $500 to $475. Jefferies analyst Brent Thill maintained a Buy rating. Microsoft shares closed at $359.84 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler slashed Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) price target from $105 to $99. Piper Sandler analyst Charles Neivert maintained a Neutral rating. Eastman Chemical shares closed at $75.53 on Friday.  <a href="https://www.benzinga.com/quote/EMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein slashed the price target for General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from $50 to $35. Bernstein analyst Daniel Roeska downgraded the stock from Market Perform to Underperform. GM shares settled at $44.18 on Friday. <a href="https://www.benzinga.com/quote/gm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $76 to $103. Citigroup analyst Paul Lejuez upgraded the stock from Neutral to Buy. Dollar Tree shares closed at $67.55 on Friday. <a href="https://www.benzinga.com/quote/dltr/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69-1024x585.png" alt="" class="wp-image-860474" style="width:569px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44665280/how-to-earn-500-a-month-from-walgreens-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Downgrades

AAPL

DLTR

FSLR

MSFT

SONO

Apple To $250? Here Are 10 Top Analyst Forecasts For Monday

Press Releases

Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery

Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

Illumina Reports Financial Results for First Quarter of Fiscal Year 2025

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications

Illumina To Webcast Upcoming Investor Conference

AVAI

MDAI

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Illumina

Illumina (ILMN) オプション

Loading...

ニュース

パートナーシップ

ベンジンガ・グローバル